Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18050479 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL14574040 | 0.90 | CHRM1 (0.60) | SMN1; SMN2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL7538580 | 0.90 | CHRM1 (0.60) | SMN1; SMN2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL7382758 | 0.89 | CA2 (0.53) | SMN1; SMN2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5372466 | 0.86 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1KMT2ALTA4HGRIK1 | |
| SCHEMBL8735264 | 0.86 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1KMT2ALTA4HGRIK1 | |
| SCHEMBL8737248 | 0.86 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1KMT2ALTA4HGRIK1 | |
| SCHEMBL8737263 | 0.86 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1KMT2ALTA4HGRIK1 | |
| SCHEMBL28807909 | 0.86 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1KMT2ALTA4HGRIK1 | |
| SCHEMBL13711847 | 0.85 | ATM (0.50) | SMN1; SMN2ALDH1A1KMT2ALTA4HSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | claimed |
| US-20030096802-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-05-22 | — | — | US | claimed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | claimed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | claimed |
| CN-1100408-A | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-03-22 | — | — | CN | claimed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| US-8569058-B2 | Nerve regeneration promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-7569608-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569609-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070043114-A1 | Nerve regeneration promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-7176240-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| EP-1685832-A1 | NERVE REGENERATION PROMOTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-02 | — | — | EP | disclosed |
| EP-1019386-A1 | REVERSE HYDROXAMATE DERIVATIVES AS METALLOPROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998038179-A1 | REVERSE HYDROXAMATE DERIVATIVES AS METALLOPROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | SMN1; SMN2 373/4885CHRM1 93/4885AKR1A1 771/4885 |
| US-20070043114-A1 | Nerve regeneration promoters | BDNF, NGF, GAP43 | SMN1; SMN2 43/4885CHRM1 2671/4885AKR1A1 2042/4885 |
| US-20030096802-A1 | Pentanoic acid derivatives | FFAR3, FPR1, FPR3 | SMN1; SMN2 138/4885CHRM1 84/4885AKR1A1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.